OpenURL Connection Search

Select item for more details and to access through your institution.

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
Published in:
Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 693, doi. 10.1177/13524585211064441
By:
- van Kempen, Zoé LE;
- Hogenboom, Laura;
- Killestein, Joep
Publication type:
Article
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
Published in:
Journal of Neuroinflammation, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12974-023-02900-z
By:
- Rodriguez-Mogeda, Carla;
- van Lierop, Zoë Y. G. J.;
- van der Pol, Susanne M. A.;
- Coenen, Loet;
- Hogenboom, Laura;
- Kamermans, Alwin;
- Rodriguez, Ernesto;
- van Horssen, Jack;
- van Kempen, Zoé L. E.;
- Uitdehaag, Bernard M. J.;
- Teunissen, Charlotte E.;
- Witte, Maarten E.;
- Killestein, Joep;
- de Vries, Helga E.
Publication type:
Article
Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.
Published in:
Frontiers in Neurology, 2022, v. 13, p. 1, doi. 10.3389/fneur.2022.1032830
By:
- van Dam, Koos P. J.;
- Hogenboom, Laura;
- Stalman, Eileen W.;
- Kummer, Laura Y. L.;
- Steenhuis, Maurice;
- Keijser, Jim B. D.;
- ten Brinke, Anja;
- van Ham, S. Marieke;
- Kuijpers, Taco W.;
- Rispens, Theo;
- Wieske, Luuk;
- Eftimov, Filip;
- Strijbis, Eva M.;
- Killestein, Joep;
- van Kempen, Zoé L. E.
Publication type:
Article
Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis.
Published in:
Annals of Neurology, 2023, v. 93, n. 1, p. 103, doi. 10.1002/ana.26534
By:
- van Kempen, Zoé L. E.;
- Hogenboom, Laura;
- Toorop, Alyssa A.;
- Steenhuis, Maurice;
- Stalman, Eileen W.;
- Kummer, Laura Y. L.;
- van Dam, Koos P. J.;
- Bloem, Karien;
- ten Brinke, Anja;
- van Ham, S. Marieke;
- Kuijpers, Taco W.;
- Wolbink, Gerrit J.;
- Loeff, Floris C.;
- Wieske, Luuk;
- Eftimov, Filip;
- Rispens, Theo;
- Strijbis, Eva M. M.;
- Killestein, Joep
Publication type:
Article

Found: 4

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis.